Main Article Content
The study aimed to examine the effects of caffeic acid-coated silver nanoparticles
(CA-AgNPs)on blood pressure, lipid metabolism, hepatic and renal function markers in
Nω-Nitro-l-arginine methyl ester (L-NAME)-induced hypertensive rats. Hypertension is induced in male albino Wistar rats by oral administration of L-NAME (40mg/kg body weight) dissolved in drinking water daily for four weeks. The rats were randomly segregated into four groups. Group I Control rats, Group II rats injected with CA-AgNPs, Group III- L-NAME rats and Group IV-L-NAME+CA-AgNPs. Group IV rats were given intraperitoneal injection of CA-AgNPs (0.5mg/kg/ml).L-NAME-induced hypertensive rats showed abnormalities including high blood pressure, increase in the levels of total cholesterol, triglycerides, free fatty acids, phospholipids, LDL-C and VLDL-C, and decline in the intensity of HDL-C comparable to normal rats. Treatment with CA-AgNPs appreciably condensed the ranges of total cholesterol, triglycerides, free fatty acids, phospholipids,
LDL-C, VLDL-C and amplified the stage of HDL-C in L-NAME hypertensive rats. Additionally, CA-AgNPs shows beneficial effectson hepatic markers such as alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT) and renal function markers such as urea, uric acid and creatinine in L-NAME induced hypertensive rats.To conclude, our data revealed that
CA-AgNPs ameliorates hypertension, improved lipid metabolism and shows beneficial effects on hepatic and renal function markers in L-NAME induced hypertension and the underlying mechanism may be attributed to reducing oxidative stress and improving antioxidants.